OA10934A - Substituted indazole derivatives ad their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors - Google Patents

Substituted indazole derivatives ad their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors Download PDF

Info

Publication number
OA10934A
OA10934A OA9800235A OA9800235A OA10934A OA 10934 A OA10934 A OA 10934A OA 9800235 A OA9800235 A OA 9800235A OA 9800235 A OA9800235 A OA 9800235A OA 10934 A OA10934 A OA 10934A
Authority
OA
OAPI
Prior art keywords
alkyl
formula
compound
daim
cyano
Prior art date
Application number
OA9800235A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA10934A publication Critical patent/OA10934A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA9800235A 1996-06-25 1998-12-11 Substituted indazole derivatives ad their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors OA10934A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (1)

Publication Number Publication Date
OA10934A true OA10934A (en) 2002-02-18

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800235A OA10934A (en) 1996-06-25 1998-12-11 Substituted indazole derivatives ad their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Country Status (43)

Country Link
US (1) US6040329A (es)
EP (1) EP0912558B1 (es)
JP (1) JP3152940B2 (es)
KR (1) KR20000022516A (es)
CN (1) CN1080260C (es)
AP (1) AP1025A (es)
AR (1) AR007456A1 (es)
AT (1) ATE244713T1 (es)
AU (1) AU716376B2 (es)
BG (1) BG64052B1 (es)
BR (1) BR9712782A (es)
CA (1) CA2258285C (es)
CO (1) CO4900056A1 (es)
CZ (1) CZ423398A3 (es)
DE (1) DE69723447T2 (es)
DK (1) DK0912558T3 (es)
DZ (1) DZ2254A1 (es)
EA (1) EA002274B1 (es)
ES (1) ES2201299T3 (es)
GT (1) GT199700075A (es)
HK (1) HK1018700A1 (es)
HN (1) HN1997000079A (es)
HR (1) HRP970350B1 (es)
HU (1) HUP9903009A3 (es)
ID (1) ID18579A (es)
IL (1) IL127036A (es)
IS (1) IS4910A (es)
MA (1) MA24225A1 (es)
MY (1) MY116915A (es)
NO (1) NO986103L (es)
NZ (1) NZ332752A (es)
OA (1) OA10934A (es)
PA (1) PA8432301A1 (es)
PL (1) PL330974A1 (es)
PT (1) PT912558E (es)
SI (1) SI0912558T1 (es)
SK (1) SK176598A3 (es)
TN (1) TNSN97108A1 (es)
TR (1) TR199802685T2 (es)
TW (1) TW434237B (es)
WO (1) WO1997049702A1 (es)
YU (1) YU60198A (es)
ZA (1) ZA975581B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2223920A3 (en) * 1996-06-19 2011-09-28 Aventis Pharma Limited Substituted azabicyclic compounds
BR9712005A (pt) * 1996-09-04 1999-08-24 Pfizer Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
ID24942A (id) * 1997-11-04 2000-08-31 Pfizer Prod Inc Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EP1244649B1 (en) * 1999-12-23 2005-03-02 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
BRPI0117198B1 (pt) 2001-12-14 2018-03-13 Merck Serono S.A. Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase
CN100381425C (zh) * 2002-07-19 2008-04-16 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑及其药物组合物和用途
MXPA05000827A (es) 2002-07-19 2005-08-29 Memory Pharm Corp Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos.
CN100513397C (zh) 2002-11-19 2009-07-15 记忆药物公司 磷酸二酯酶4抑制剂
RU2379292C2 (ru) * 2003-04-18 2010-01-20 Мемори Фармасьютиклз Корпорейшн Производные пиразола в качестве ингибиторов фосфодиэстеразы 4
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CN101166733A (zh) 2004-10-15 2008-04-23 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2493889B1 (en) * 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (es) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
SK279958B6 (sk) * 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
CN1050129C (zh) * 1994-10-20 2000-03-08 美国辉瑞有限公司 二环四氢吡唑并吡啶和其作为药物的应用

Also Published As

Publication number Publication date
ES2201299T3 (es) 2004-03-16
DZ2254A1 (fr) 2002-12-18
EA199801047A1 (ru) 1999-06-24
SK176598A3 (en) 2000-06-12
BG103056A (en) 1999-10-29
DK0912558T3 (da) 2003-08-18
EA002274B1 (ru) 2002-02-28
HRP970350B1 (en) 2003-04-30
NZ332752A (en) 2001-04-27
HRP970350A2 (en) 1998-06-30
HN1997000079A (es) 1997-12-26
ID18579A (id) 1998-04-23
YU60198A (sh) 1999-09-27
NO986103D0 (no) 1998-12-23
JPH11514668A (ja) 1999-12-14
EP0912558A1 (en) 1999-05-06
PT912558E (pt) 2003-11-28
JP3152940B2 (ja) 2001-04-03
IS4910A (is) 1998-11-27
TR199802685T2 (xx) 1999-03-22
ZA975581B (en) 1998-12-24
NO986103L (no) 1998-12-23
CN1080260C (zh) 2002-03-06
AU716376B2 (en) 2000-02-24
CA2258285A1 (en) 1997-12-31
CA2258285C (en) 2002-11-26
HK1018700A1 (en) 1999-12-30
MA24225A1 (fr) 1997-12-31
HUP9903009A2 (hu) 2000-05-28
PA8432301A1 (es) 1999-12-27
DE69723447D1 (de) 2003-08-14
EP0912558B1 (en) 2003-07-09
WO1997049702A1 (en) 1997-12-31
PL330974A1 (en) 1999-06-21
BR9712782A (pt) 1999-12-07
TW434237B (en) 2001-05-16
KR20000022516A (ko) 2000-04-25
DE69723447T2 (de) 2003-12-24
SI0912558T1 (en) 2003-10-31
IL127036A0 (en) 1999-09-22
TNSN97108A1 (fr) 2005-03-15
ATE244713T1 (de) 2003-07-15
AP1025A (en) 2001-11-19
IL127036A (en) 2001-06-14
CO4900056A1 (es) 2000-03-27
HUP9903009A3 (en) 2002-01-28
CZ423398A3 (cs) 1999-12-15
CN1223651A (zh) 1999-07-21
GT199700075A (es) 1998-12-04
MY116915A (en) 2004-04-30
AR007456A1 (es) 1999-10-27
BG64052B1 (bg) 2003-11-28
AU2785797A (en) 1998-01-14
US6040329A (en) 2000-03-21
AP9701020A0 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
OA10934A (en) Substituted indazole derivatives ad their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
US6262040B1 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
US6211222B1 (en) Substituted indazole derivatives and related compounds
CA2208792C (en) Substituted indazole derivatives
WO2001062738A1 (fr) Composes a base d'imidazoline
WO2007032466A1 (ja) 複素環化合物、その製造方法並びに用途
AU2019353144B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
KR20220141331A (ko) P2x3 조정제
WO2005049601A1 (en) Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
JPS58148862A (ja) 置換フエニルピラゾ−ル誘導体
CZ71099A3 (cs) Deriváty indazolu, farmaceutické kompozice na jejich bázi, meziprodukty a způsob léčení chorob
CA2201728A1 (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
NZ547469A (en) 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors